Bone radiotherapy (RT) is a foundation of the discipline and represents a significant portion of many practices. The standard protocols for palliative RT (8Gy x 1, 4Gy x 5, etc.) were pioneered almost 50 years ago, when systemic therapies were far less useful.

Tumor phylogenetics (or cancer phylogenetics) is the scientific method used to consider cancer biology through the lens of computational evolutionary biology.

FLASH radiation therapy (FLASH-RT), delivered with ultra high dose rate (UHDR), may allow patients to be treated with less normal tissue toxicity for a given tumor dose compared with currently used conventional dose rate.

This activity, sponsored by the ASTRO Early Career Committee, provides learners with opportunities to engage with common topics crucial in the early career period, including contract negotiation, financial planning and academic promotion.

Breast cancer recurrence after prior definitive multimodality treatment is an increasingly common clinical situation faced by practitioners, with long-term new primary or recurrent non-metastatic locoregional recurrence developing not infrequently over 10 years following initial treatment.

This is a case-based panel activity, with a surgeon, a medical oncologist and a radiation oncologist. Each speaker reviews the current and ongoing studies addressing treatment de-intensification in their area of expertise.

The use of HPV ctDNA in the clinical management of patients with HPV-associated oropharyngeal squamous cell carcinoma is rapidly increasing; however, questions remain regarding its utility and validity in various clinical settings.

This case-based activity is designed to provide learners with practical guidance on management of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) and highlight areas of uncertainty where there may be a range of acceptable treatment approaches.

This activity focuses entirely on issues related to the Organs at Risk (OAR) in the setting of thoracic radiation. Discussion centers on protecting the OARs and managing acute and late toxicities. Each speaker focuses on a different clinical situation.